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Research highlights: 
 Neurodevelopmental disorders (NDDs) are severely debilitating neuropsychiatric illnesses. 
 NDDs are caused by aberrant brain development, and have strong genetic causes and risk factors.  
 NDDs are also modulated by various environmental factors, and can be modeled experimentally. 
 Animal models are a valuable tool to mimic a wide spectrum of NDDs and related conditions. 
 Here, we discuss the neurobiological mechanisms of selected NDDs and their experimental models. 
 
Abstract 
Neurodevelopmental disorders (NDDs) are a heterogeneous group of prevalent neuropsychiatric 
illnesses with various degrees of social, cognitive, motor, language and affective deficits. NDDs are 
caused by aberrant brain development due to genetic and environmental perturbations. Common NDDs 
include autism spectrum disorder (ASD), intellectual disability, communication/speech disorders, 
motor/tic disorders and attention deficit hyperactivity disorder. Genetic and epigenetic/environmental 
factors play a key role in these NDDs with significant societal impact. Given the lack of their efficient 
therapies, it is important to gain further translational insights into the pathobiology of NDDs. To address 
these challenges, the International Stress and Behavior Society (ISBS) has established the Strategic Task 
Force on NDDs. Summarizing the Panel’s findings, here we discuss the neurobiological mechanisms of 
selected common NDDs and a wider NDD+ spectrum of associated neuropsychiatric disorders with 
developmental trajectories. We also outline the utility of existing preclinical (animal) models for building 
translational and cross-diagnostic bridges to improve our understanding of various NDDs. 
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1. Introduction 
Neurodevelopmental disorders (NDDs) are heritable psychiatric illnesses with overt social, 
motor, cognitive and affective disabilities that are caused by abnormal brain development [20, 28, 114]. 
Although deficits in neurogenesis, glial and neuronal proliferation, migration, synapse formation and 
myelination occur during early embryogenesis [57, 67, 92, 162], they evoke lasting behavioral and 
neurological deficits in NDD children and adults [88, 176].  
NDDs form a heterogeneous group of illnesses with varying severity and clinical manifestations 
(Fig. 1). One of the most common NDDs is intellectual disability (ID) - a spectrum of impaired mental 
functions in conceptual (e.g., language, mathematics, memory, knowledge, logic), social (e.g., 
empathy/compassion, social judgment, communication and interaction skills) and practical (e.g., personal 
care, occupational responsibilities, hobby) domains [4]. Communication disorders (CD) present as 
difficulties with language, speech, phonetic fluency or social communication, including language and 
speech/sound disorders, childhood-onset stuttering and social (pragmatic) CD [4]. Attention deficit 
hyperactivity disorder (ADHD) manifests in inattention and increased hyperactivity-impulsivity [4]. 
Specific learning disorder involves difficulties in learning skills, such as reading, writing, spelling or 
mathematic calculations [4]. Autism spectrum disorder (ASD) is characterized by persistent reciprocal 
social deficits in communication and interaction, with restricted, repetitive patterns of behavior, interests 
or thoughts [4]. ASD also includes high-functioning autism (Asperger’s), Angelman syndrome (AS, 
characterized by severe ID, seizures, sleep deficits, motor stereotypies and positive emotionality) [4] and 
X-linked Fragile X syndrome (FXS, caused by mutant Fragile X mental retardation 1 (FMR1) gene) with 
social deficits, ID and stereotypic behaviors [167]. Rett syndrome represents another common ASD-
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related NDD, affecting females and causing stereotyped hand movements, microcephaly (see further), as 
well as cognitive and social deficits [137]. 
Motor disorders present with impaired execution of motor skills, or repetitive motor behaviors, 
including developmental coordination and stereotypic movement disorders [4] (Fig. 1). Tic disorders are 
characterized by habitual motor movements or vocalizations which are sudden, rapid, recurrent and non-
rhythmic. This group of NDDs includes Tourette’s disorder, persistent (chronic) motor or vocal tic 
disorder, provisional tic disorder, as well as other tics [4]. Tuberous sclerosis complex (TSC) is 
characterized by benign brain tumors (tubers), often presenting with ID and varying developmental 
delays [46]. Structural brain disorders, such as microcephaly and lissencephaly, form a distinct group of 
NDDs with specific genetic and environmental causes [92]. Microcephaly, diagnosed as head 
circumference two standard deviations below the mean for a child's age and sex, often co-occurs with ID 
and speech delays [197]. Lissencephaly is a rare genetic disorder that results in a brain lacking gyri and 
folding, and manifests behaviorally in seizures, hypotonia, and ID resulting from the overall psychomotor 
impairment [69].  
Finally, specific environmental factors can also trigger NDD pathogenesis. For example, prenatal 
exposure to alcohol is a key risk factor for a range of morphological phenotypes and mental retardation 
collectively referred to as Fetal Alcohol Syndrome (FAS, Fig. 1) [101]. FAS represents the main non-
hereditary cause of ID, affecting approximately 2-5% of live births [129]. Relatively low doses of alcohol 
can also affect cognition, behavior and brain morphology (referred to as Fetal Alcohol Spectrum 
Disorders, FASD), implicating even moderate drinking during pregnancy as a risk for NDD pathogenesis 
[82, 163, 169, 182] (see further). 
In general, NDDs are severely debilitating brain illnesses (Fig. 1) with significant societal impact 
[61]. Given the lack of efficient targeted therapies, it is important to gain further translational insights 
into the pathobiology of these disorders [88]. To address this problem, the International Stress and 
Behavior Society (ISBS) has established the Strategic Task Force on NDDs, an international team of 
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independent clinical and preclinical experts [88]. Complementing the Panel’s recommendations on 
improving NDD pharmacotherapy [88] and preclinical behavioral models [2], here we discuss the 
neurobiological and genetic mechanisms of several common NDDs, and outline further strategic 
directions of research of their key affected (social, cognitive and motor) domains. This review does not 
intend to provide a comprehensive coverage of all NDDs, and acknowledges the existing limitations of 
animal (preclinical) models of these disorders. 
2. Genetics of neurodevelopmental disorders 
NDDs are highly heritable disorders [20, 28, 114]. While recent genetic technology has enabled 
the identification of numerous genes for various NDDs [91], their exact pathogenetic mechanisms remain 
unclear [206]. Our understanding of NDDs is complicated by their polygenic nature and de novo 
mutations in multiple genes (often resulting in similar clinical phenotypes) identified by whole-exome 
and whole-genome sequencing [94, 131, 146, 184]. Novel mutations are recurrently seen in such key 
cellular genes as CHD8, DYRK1A, GRIN2B and PTEN [145], thereby affecting normal growth and 
development of the brain. Genetic analyses empower the search for candidate genes for NDDs, whose 
psychiatric symptoms co-occur with other, non-mental phenotypes (e.g., altered facial morphology and 
cardiac defects) [19, 29]. For example, FXS is caused by the expanded CGG repeat in the promoter of 
the FMR1 gene [71, 193], resulting in distinguishing facial features [121], ID, speech delay and repetitive 
behaviors [18, 206]. FMR1 codes for the fragile X mental retardation protein (FMRP), which acts as a 
negative regulator of mRNA translation in neurons [143], and its genetic ablation in mice markedly 
decreases dendritic spine density in the brain - a phenotype also seen in human postmortem FXS samples 
[41, 95, 143].  
Caused by loss of one copy of the UBE3A (Ubiquitin Protein Ligase E3A) gene [110, 125, 128], 
AS-related ID, stereotyped behavior and hyperactivity [9, 40] parallel decreased dendritic spine density 
and impaired long-term potentiation/depression seen in Ube3a knockout rodents [168, 200]. In general, 
such common deficits in dendritic spine density in NDDs highlights the importance of synaptic processes 
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in neural development [205, 206]. For instance, mutations in SHANK3 (encoding a scaffolding synaptic 
protein [134, 166, 187]) cause developmental delay, neonatal hypotonia, decreased socialization and 
increased stereotypy clinically [152]. Similar to SHANK3, the neuroligin and neurexin protein families 
involved in synaptic scaffolding, are also implicated in ASD [206]. Mutations in the NEUROLIGIN3 
(NLGN3) and NEUROLIGIN4 (NLGN4) genes were among the first causative mutations identified in 
ASD patients [98]. In line with this, Nlgn knockout mice show specific deficits in excitatory (Nlgn1) or 
inhibitory (Nlgn2) synaptic transmission [39], and social deficits (nlgn3 and nlgn4), a key behavioral 
symptom of ASD [98, 158].  
Mutations in MECP2 (encoding the methyl-CpG-binding protein 2, MeCP2) are responsible for 
the majority of cases of Rett syndrome [137], which is highly comorbid with ASD. MeCP2 is abundant 
in post-mitotic neurons and binds to methylated cytosines in DNA [117, 174], functioning as both a 
transcriptional repressor and activator [32, 188]. Implication of genes encoding chromatin-modifying 
enzymes in ASD [51] is not surprising, given the association of MECP2 with Rett syndrome [33, 78]. 
Likewise, Mecp2 mice are a useful model of human Rett syndrome [33, 36, 77, 174], showing aberrant 
synaptic plasticity and deficient long-term potentiation in genetic knockout [15, 132]. Interestingly, 
targeted deletion of Mecp2 in gamma aminobutyric acid (GABA)-ergic neurons recapitulates many core 
Rett phenotypes, including reduced GABA-ergic neurotransmission [35].  
Recently identified risk genes for ID include SYNGAP1 (encoding the synaptic Ras-GTP 
activating protein 1) and SNAP25 (encoding synaptosomal-associated protein 25) regulating synaptic 
signaling and neurotransmission, respectively [75, 81, 105]. SNAP25 is also a risk locus for ADHD, along 
with genes encoding proteins involved in dopaminergic and serotonergic neurotransmission, such as 
dopamine receptors D4 (DRD4) and D5 (DRD5), dopamine transporter DAT (SLC6A3), serotonin 
transporter SERT (SLC6A4), and serotonin 1B receptor (HTR1B) [74, 119]. In summary, these and many 
other examples, including Down, Williams, Prader-Willi and Angelman syndromes and even 
schizophrenia (Table 1), strongly support the critical role of genetic factors in both clinical NDDs and 
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their genetic animal models, collectively providing important mechanistic insights into pathobiology of 
NDDs. 
3. Environmental factors influencing risk for NDDs 
In addition to genetic determinants, a wide range of environmental factors can impact neural 
development (Fig. 2). Beginning in utero, these postconception influences involve the nutritional and 
physiological (e.g., hormonal or infectious) status of the mother, as well as her lifestyle and use of 
medications (e.g., selective serotonin reuptake inhibitors, SSRIs or valproate) [45, 59, 122]. Some of 
these factors, such as postnatal nutrients, hormones, infections, the microbiome and parenting, potently 
modulate neural development [100, 113, 142], and will be discussed here in detail.  
3.1 Pre-natal environmental factors modulating neural development 
The placenta transfers nutrients, hormones, drugs and inflammatory factors from the mother to 
the fetus. For example, placental function affects perfusion of the fetus, and therefore can influence neural 
development. Nutritional factors, consumed by the mother and relevant for fetal neurodevelopment, 
include fat-soluble vitamins (e.g., A, D, E), tryptophan and nutrients related to single carbon metabolism 
(e.g., choline, vitamins B2, B6, B12 and folate) [59, 60]. Tryptophan, a food-derived essential amino 
acid, serves as a precursor of serotonin and melatonin, but is also subject to degradation by indoleamine 
2,3-dioxygenase, one of three enzymes catalyzing the first step of the kynurenine pathway of tryptophan 
degradation. While melatonin is one of the main sources of mitochondrial protection, it acts as antioxidant 
in the placenta and, as shown in mouse studies, facilitates the transport of folate from maternal circulation 
through the placentas into the fetus [70]. Folate deficiency has been associated with neural tube defects 
[47] and, as a B-vitamin, is important for CNS cell repair [96], genome epigenetic modulation [179] and 
immune mechanisms [111].  
As already mentioned, exposure to alcohol during pregnancy is a key risk factor in NDDs, such 
as FAS [101] and FASD [82, 163, 169, 182]. Sonic hedgehog (SHH) signaling is of special interest in 
FAS owing to its role in proper craniofacial development. During early neural crest migration, ethanol 
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reduced Shh mRNA expression in the chick embryo and caused cell death in cranial neural crest cells, an 
effect rescued by exogenous Shh administration [3]. FAS and FASD are closely related to the umbrella 
term “alcohol-related neruodevelopmental disorder” (ARND), representing a facet of NDD pathogenesis 
associated with history of maternal alcohol exposure (Fig. 1). In addition to rodents, other newly 
emerging model organisms, such as zebrafish (Danio rerio), can be useful to study various aspects of 
FAS and ARND. For example, zebrafish models link early ethanol effects with aberrant craniofacial 
morphology [22], as well as deficits in social behavior and increased perseveration on a learning task 
[149, 150]. These behavioral changes corresponded to changes in nicotinic, dopaminergic, serotonergic 
and µ-opioid receptor gene expression, suggesting that ethanol during development impacts 
neurotransmitters and receptor expression, causing long-term behavioral effects. The effects of prenatal 
exposure to ethanol is dependent on the timing of exposure and the dose to which the fetus is exposed, 
but may also depend on the fetal and maternal genotype. A screen of alcohol-exposed mutant zebrafish 
revealed several alcohol-sensitive alleles [183], including the gene encoding platelet derived growth 
factor receptor α (pgdfra), a mitogen involved with neural crest cell migration and causing craniofacial 
abnormalities in 63% of heterozygotes after exposure to 1% alcohol. This finding is particularly 
interesting as it revealed alcohol-induced haploinsufficiency and was also identified as a potential locus 
of interest in a GWAS of humans with FAS. Similarly, the PCP gene vangl2, which is responsible for 
neural tube development, is associated with an increased risk of ethanol-induced teratogenesis in 
heterozygotes, revealing ethanol-induced haploinsufficiency that merits special interest from the 
NDD/ARND perspective [183]. 
3.2. Other parental influences 
Post-conception maternal stress has a major impact on fetal neural development, especially given 
mounting evidence that early life stress increases risk to various childhood/adulthood disorders. For 
instance, maternal stress during pregnancy is associated with an increased incidence of ADHD and ASD, 
as well as cognitive deficits and emotional/behavioral problems in children later in life [141]. Animal 
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studies suggest that the neuroendocrine hypothalamic–pituitary–adrenal (HPA) axis is particularly 
vulnerable to early-life programming by stress and subsequent epigenetic modification of 
glucocorticoids-related genes [123]. Since glucocorticoids promote neuronal survival and differentiation, 
myelination, dendritic growth and synaptogenesis [107], maternal stress can have a substantial impact on 
fetal neural development and increase the risks for NDDs [196]. Pregnancy itself is a risk factor for 
various brain disorders, such as depression. Because of the detrimental effects of maternal depression on 
mother and fetus, mothers may receive antidepressant pharmacotherapy during pregnancy, including 
SSRIs. However, SSRIs readily cross the placenta in both humans and mice [139] and can alter serotonin 
homeostasis, thereby affecting neural development. Prenatal SSRI exposure in mice increases anxiety in 
later life, similar to phenotypes of SERT mutant mice [11]. Clinical studies also report that prenatal SSRI 
exposure has neurodevelopmental consequences for offspring, ranging from newborn withdrawal 
symptoms [133] to delayed motor development, socio-emotional changes [83], ASD [23, 45, 63] (but see 
[31]) and ADHD [66]. Given similar neurodevelopmental consequences of prenatal SSRI exposure in 
rodents [106, 109], changes in neurotransmitter levels during early brain development may have a major 
impact on NDD-related phenotypes. Another common example of NDD-relevant prenatal drug exposure 
is valproic acid. Prescribed for maternal epilepsy and some neuropsychological disorders, this agent 
significantly increases risk for ASD in humans [38], and its early exposure causes similar ASD-like 
behavioral deficits in a wide range of animal models, including rodents [170], tadpoles [99] and zebrafish 
[16]. 
Fetal immune activation (e.g., as a result of maternal infections) may also modulate neural 
development. These immune interactions are complex, as maternal placenta itself contains natural killer 
cells and macrophages [64] – the immune cells that can influence the development of the placenta. This, 
in turn, can affect the fetal microenvironment (e.g., by modulating the perfusion of the fetus) [126]. 
Furthermore, cytokines induced by maternal immune activation and maternal antibodies can cross the 
placenta [203], which can exert a negative impact on brain development if the time of exposure overlaps 
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with major processes in neurodevelopment, such as cell migration, axonal elongation and dendritic tree 
maturation [21]. While this may increase the risk of NDDs [53] [30, 85], peripheral activation of the fetal 
immune system can also modulate the CNS indirectly, by activating the HPA axis [177]. Because the 
blood-brain barrier is not fully developed during the fetal period, larger molecules, such as antibodies, 
may have greater access to the brain [55]. The blood-brain barrier permeability increases as a result of 
microglia cell activation, infection, trauma or stress, therefore enhancing the risk of exposing the brain 
to insults and environmental stimuli that affect neural development [156].  
Another important factor in fetal neural development is maternal genotype. For example, maternal 
SERT promoter region 5-HTTLPR genotype affects the development of children, with their neuroimaging 
phenotypes and cognitive performance differing between the 5-HTTLPR SS and LL mothers [190]. 
Although all children carried the L/S genotype, somatosensory cortex grey matter density and fine motor 
task performance were greater in children of the SS mothers [190]. In another human study, familial 
analyses of the tryptophan hydroxylase 1 gene TpH1 mutation carriers (that have deficiency in serotonin 
production in the periphery, but not in the brain) revealed that offspring of mothers carrying TpH1 
mutations exhibited higher ADHD scores and related symptoms than did controls or offspring of fathers 
with the corresponding TpH1 mutations [79]. Similarly, mouse fetuses (fully capable of producing 
serotonin in the brain) conceived by a TpH1 knockout mother deficient in the peripheral serotonin, had 
an abnormally shaped cortex [42, 144]. Thus, prenatal influences and maternal genotype have profound 
effects on neural development in offspring, and are therefore highly relevant to NDD pathogenesis. 
3.3. Post-natal environmental factors modulating neural development 
Microbiome is a key post-natal environmental factor to consider for NDDs, since gestational age, 
mode of delivery, bacterial environment and use of antibiotics can all influence the composition of the 
gut microbiota of the newborn [100, 144]. For example, bacteria in the gut influence the immune system, 
as well as tryptophan availability and peripheral monoamine levels [144]. Germ-free animals exhibit 
increased plasma tryptophan concentrations which can be normalized by colonization immediately post-
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weaning [144]. Germ-free mice show robust changes in the brain, including increased hippocampal 
serotonin concentrations - an alteration resistant to the subsequent normalization of circulating 
tryptophan following the introduction of a gut microbiota immediately post-weaning [144]. Although 
peripheral tryptophan may be converted to serotonin in the brain, it can also be subject to the indoleamine 
2,3-dioxygenase pathway, being converted to kynurenine and therefore becoming unavailable for 
serotonin synthesis [201]. Microbiota influence the kynurenine:tryptophan balance [144], and this shift 
towards kynurenine activates the immune system [48], thereby indirectly affecting postnatal neural 
development.  
Parenting per se also has a major impact on postnatal neural development. A well-known example 
is the effect of maternal adversity in humans and rodents on development of offspring [7]. In humans, 
childhood maltreatment (often dependent on parent-offspring social interactions) is associated with an 
increased HPA response to stress [7]. In rodents, low maternal grooming of pups increases stress 
reactivity of the HPA-axis by altering serotonin-dependent epigenetic regulation of glucocorticoid 
receptors in the hippocampus and the glucocorticoid negative feedback [6, 7]. These effects are also 
accompanied by changes in dendritic morphology of hippocampal pyramidal neurons and pronounced 
behavioral effects, such as reduced exploration, appetitive behavior and escape from threat, and increased 
fear-related memories [7] [34].  
Other environmental factors, including environmental enrichment (EE) and exercise, have been 
investigated as potential interventions for NDDs in animal models. For example, in a rat ASD model 
involving prenatal valproic acid exposure, EE reversed many ASD-like phenotypes, including repetitive 
behaviors, decreased social interactions and increased anxiety [171]. The restricted and repetitive 
behaviors seen in ASD may be particularly modifiable by EE [118, 161]. Exercise also has beneficial 
effects on neural function and neuroplasticity, and may confer resistance to stressful stimuli occurring 
during crucial developmental periods [116, 153]. For example, symptoms of ADHD show some 
improvement following bouts of exercise, and scheduled exercise along with EE has been proposed as 
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an adjuvant treatment for ADHD [80]. Clearly, future studies should continue to investigate the 
remediation of NDDs by environmental factors including EE and exercise in both clinical and preclinical 
settings, as these may offer cost-effective benefits for the patients.  
4. Emerging translational challenges 
Taken together, mounting evidence summarized here demonstrates a complex interplay between 
genetic and environmental factors underlying NDD pathogenesis in both clinical and preclinical studies 
(Fig. 1-2). The issue of how well animal models translate into clinical NDDs and other brain disorders 
has already been comprehensively discussed in the literature (including recent reviews of the scope, 
validity and challenges of translation of preclinical models [103, 104, 136, 181, 191, 192]), and will not 
be addressed here. Fully recognizing the existing limitations of animal NDD models, the ISBS Task 
Force has emphasized several strategies to address the existing challenges in this field of biological 
psychiatry. Identified by the Panel as critical areas of research to build translational and cross-diagnostic 
bridges, these studies can improve markedly our understanding of NDD neurobiology. 
4.1 Improving the pharmacotherapy of NDDs: understanding molecular targets 
Although varying in the central and genetic causes or in their clinical symptoms, NDDs can 
respond to drug therapies that target discrete deficits (Table 2) [88]. The degree of genetic anomalies and 
brain pathology underlying NDDs determine the potential targets for pharmacotherapy. For example, 
comparable cognitive improvements are less likely for NDDs associated with severely underdeveloped 
brain regions, such as FAS or microcephaly [58]. The prognosis of pharmacotherapy is better for NDDs 
caused by subtler neural changes that affect the function of local, well-defined neural circuits. Likewise, 
targeting dysfunction in long-term plasticity, including both synapse strengthening via long-term 
potentiation and weakening by long-term depression, appears to be rather efficient [124]. In some cases, 
an effective therapy may involve drugs given to infants or young children [84], thereby requiring a well-
timed diagnosis. Pharmacotherapies that target disrupted equilibrium of neurotransmitter systems also 
offer promise for NDDs, since drugs that counter such imbalances affect ongoing neural circuit dynamics 
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rather than established gross anatomical abnormalities. Examples of therapeutic strategies in this category 
include the use of GABA antagonists for Down syndrome [65], mGluR antagonists for FXS [17], and 
norepinephrine reuptake inhibitors for Rett syndrome [165, 202]. Finally, functional homeostatic 
mechanisms may contribute to the rebalancing of neurotransmitter function after drug therapy [65], and 
different therapeutic strategies for NDDs may be required at different stages of life [88]. Thus, a major 
task is to find a critical ‘core’ deficit among multiple neurological processes at a sensitive time window 
in NDDs, and then quickly adjust their pharmacotherapy accordingly. 
4.2. Expanding NDD spectra beyond traditional diagnostic categories: understanding clinical 
targets across disorders  
Recently developed and promoted by NIMH research diagnostic criteria (RDOCs) [93] 
emphasize the importance of pathobiological mechanisms and aberrant traits across multiple disorders. 
This approach aims to lay a firmer foundation for discovering the distal etiology of brain diseases, which 
are presently only recognized by their clinical depictions in the DSM and the ICD. Various psychiatric 
disorders have recently been reconsidered in the context of neural development, as genetic risk and 
environmental factors may jointly predispose an individual to pathogenesis beyond traditional NDDs, 
such as depression, anxiety and schizophrenia. For example, early studies have identified an increase in 
minor physical abnormalities in adult patients with major depression [120], suggesting some 
neurodevelopmental origin of depressive symptoms. Although subsequent studies did not replicate these 
findings [185], recent hypotheses of depression pathogenesis recognize the importance of early 
environmental modulation and developmental trajectories in adult affective states [10]. For instance, risks 
from genes related to monoaminergic neurotransmission and neurotrophic factors, such as BDNF, may 
be combined with aversive environmental conditions during development, to increase depression risk 
[89]. Likewise, the neurodevelopmental hypothesis of schizophrenia has gained traction recently, 
especially as genetic association studies have revealed significant risk overlap with ASD and ID in 
networks related to chromatin remodeling and synaptic connectivity [1, 68, 130]. Subsequent meta-
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analysis also revealed significant co-morbidity between ASD and schizophrenia [37]. Genetic 
schizophrenia risks involve common variation across the genome, particularly in the major 
histocompatibility complex (MHC) region and the complement component 4 [172, 180]. Genetic 
predisposition and environmental factors affecting brain development therefore encompass schizophrenia 
risk, suggesting that NDDs represent, in fact, a much wider ‘NDD+’ spectrum of abnormalities [140, 
147] (Fig. 1).  
Individuals exposed to intense trauma are also at significant risk for developing post-traumatic 
stress disorder (PTSD) or other trauma- and stressor-related disorders (TSRDs) [87, 186, 207]. Childhood 
abuse/trauma can result in an early-onset PTSD, suggesting that this subset of TSRDs may be related to 
NDDs [8, 27, 151]. TSRDs are difficult to treat because stress interacts with vulnerability factors [62, 
112, 159, 160], differentially affecting traumatized individuals [86, 135, 138, 159]. Neurodevelopmental 
deficits (e.g., reduced hippocampal volume) per se may predispose individuals to PTSD [27, 135], with 
‘early’ traumas making it more treatment-resistant [127]. Thus, neurodevelopmental factors may play a 
dual role in TSRDs: while some stressors may induce them at young age (thereby influencing neural 
development), other stressors can trigger pathogenesis in vulnerable adults with pre-existing 
neurodevelopmental abnormalities (Fig. 2) [56, 155, 175, 207]. For example, individual responses to 
trauma are influenced by a history of childhood abuse or neglect [8, 27, 151], causing neuroendocrine 
deficits and dysfunction of forebrain structures (e.g., the hippocampus and prefrontal cortex [25, 26, 
194]), and sensitizing vulnerable individuals to respond more strongly to stress in adulthood [127, 148]. 
A recent animal PTSD model utilizes a 1-month daily inescapable confinement of rats close to a cat, 
combined with daily social stress [208, 209]. Using this and other preclinical TSRD models [49, 155] 
can be particularly interesting in neurodevelopmental contexts – e.g., assessing how trauma in mothers 
affects neural development of offspring, or how early stress in pups alters their adult NDD-related 
behaviors. Moreover, in addition to NDD-promoting impact of early traumas, it is also possible that, 
under certain circumstances, such exposure can also increase resistance (somewhat similar to how 
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vaccinations boost the immune system). Therefore, the fine balance between NDD-triggering and 
protective impacts of early life experiences merits further scrutiny in both clinical and pre-clinical studies. 
Accordingly, more ‘spectrum-based’ integrative animal models to target this growing ‘NDD+’ group 
may be needed [102, 181]. 
4.3 Tracing NDDs across the lifespan: understanding potential therapeutic windows 
Other important emerging questions are how the brain develops under healthy conditions, and 
how this goes awry in NDDs? The former needs to be clear by establishing the latter. As brain 
development is driven by a complex interplay of genetic and environmental determinants [54, 178], 
animal models are particularly useful for tracing neural development across developmental stages. For 
example, micro-array gene expression and high-throughput RNA-sequencing of the mouse brain across 
developmental stages, from infancy (postnatal day P7), adolescence (P28) to adulthood (P70), shows that 
the overall increase in gene expression from infancy to adolescence, which decreases in adulthood [173, 
198]; see Fig. 3 for an overview of gene expression changes across development. The adolescent brain 
has the most active gene expression, especially of regulatory genes and transcription factors critical for 
neurogenesis, differentiation, glial lineage determination and circadian rhythm regulation. Compared to 
infant brains, adolescent and adult brains also show a drastic increase in myelin basic protein-coding 
gene expression [198]. During infancy and adolescence, gene expression related to axon repulsion and 
attraction show opposite trends, as axon attraction is activated at the embryonic stage and declines 
postnatally [198]. Animal studies can detail developmental processes in neurons, astrocytes, microglia, 
endothelial cells, pericytes and various maturation states of oligodendrocytes, given that the major brain 
cell classes differ in their developmental processes. In the P7 mouse cortex, RNA sequencing reveals 
many new cell type-enriched genes and splicing isoforms, substantially enhancing our understanding of 
brain developmental processes (http://web.stanford.edu/group/barres_lab/brain_rnaseq.html). Novel 
long non-coding RNAs (lncRNAs) were also identified in proliferating neural stem cells, differentiating 
progenitors and newborn neurons, which overlapped with neurogenic genes and shared a nearly identical 
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expression pattern [13]. This suggests that lncRNAs control corticogenesis by tuning the expression of 
nearby cell fate determinants. Finally, during cortical development, a group of novel small non-coding 
RNAs (sncRNAs) is associated with much higher editing events at late postnatal stages (P7, P14, P28), 
implicating sncRNA editing in fine tuning of gene expression during the formation of complicated 
synaptic connections at postnatal stages [199]. Empowered by the availability of in-vivo animal models, 
such approaches may help improve our understanding of neurodevelopmental trajectories in the healthy 
brain as well as in NDDs. Clearly, studying gene expression at the end point/time of disease 
manifestation, is insufficient to understand what goes wrong during development. This necessitates 
systematic studies generating timelines for genetic or environmental NDD animal models and may reveal 
time windows responsive to early interventions that reduce successive abnormal neurodevelopmental 
processes. 
4.4. The role of epigenetic modulation: bridging genetic and pharmacological therapies 
As both genetic and environmental factors impose risk for NDDs, epigenetic enzymes and 
modification rapidly emerge as potential avenues for investigation of biological mechanisms and novel 
pharmacological therapies. Indeed, mutations in specific epigenetic enzymes may cause some NDDs 
(e.g., mutations in MECP2 in Rett syndrome) [5]. Recent genome-wide studies have identified de novo 
mutations in numerous genes involved in chromatin modification present in patients with ASD [24, 50]. 
Other genes identified in these same studies include synaptic organization proteins, and it is possible that 
these two biological networks may be more closely related than previously assumed. For example, the 
chromatin-modifying gene CHD8, which is associated with ASD, modulates the transcription of other 
ASD risk genes during neural development [43]. Given the involvement of environmental factors in the 
etiology of NDDs, epigenetic alterations occurring during early life, from gestation to adolescence and 
young adulthood, may confer increased or decreased risk for these disorders [43]. As whole-genome 
sequencing becomes more economically viable, mutations in non-coding, regulatory regions in ASD 
patients have been observed recently [189]. Additionally, ASD patients show differential expression of 
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lncRNAs compared to controls [195] The notion of transgenerational epigenetic effects, where risk for a 
disease may be passed along outside of traditional genetic encoding, may also play a role in NDD risk. 
For example, prenatal nicotine exposure in rodents causes hyperactivity that resembles ADHD, and this 
phenotype is inherited (presumably, epigenetically) until at least the third generation via the maternal 
lineage [204]. Further exploration of epigenetic enzymes, transgenerational effects, and regulatory 
regions of the genome can shed additional light on the pathogenesis of complex NDDs.  
 
5. Conclusion 
In summary, various genetic and environmental risk factors predispose to NDDs, affecting both 
the brain development and its mature functioning. Despite the growing scientific inquiry into the 
pathogenesis of NDDs, their etiology and effective treatment strategies remain unclear. NDDs also 
significantly overlap with other prevalent psychiatric disorders, including schizophrenia, depression and 
PTSD, possibly representing an even broader ‘NDD+’ spectrum of brain maladies resulting from 
developmental perturbations (Fig. 1). Continued effort into improving pharmacotherapy and identifying 
genetic and environmental risk factors for NDDs will implicate novel biological pathways and, hopefully, 
improve clinical outcomes. As many genetic and environmental factors influence neural development, 
they can do so both independently and in interaction. Thus, environmental factors can impinge on 
genotype-driven divergent neural development at varying time points, both pre- and postnatally. While 
it is not feasible to address in one experiment all possible genotype x environment x time interactions, 
this complexity must be considered when interpreting clinical or experimental neurobehavioral data.  
The ultimate goals of understanding the etiology of NDDs are to direct treatments at 
neurodevelopmental deficits, to apply them during a most sensitive time window, and/or early enough in 
order to prevent or reduce aberrant neural development. Since genes and environmental factors often act 
prenatally, this may also require ‘very early’ diagnostic and therapeutic intervention, such as treatment 
of the mother during pregnancy. However, like using prenatal SSRIs to alleviate maternal depression and 
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protect the fetus for glucocorticoid-mediates changes in neural development [90, 106], this may also 
result in a catch-22 situation with side effects of the remedy overweighting its therapeutic action. 
Therefore, finding the appropriate intervention before disease symptoms are displayed is not trivial, and 
must be considered from neurodevelopmental perspective, in addition to other (primary) goals of 
therapeutic intervention.  
On a positive note, children and adults suffering from NDDs may also have their strong 
phenotypic characteristics. Therefore, rather than only correcting NDD deficits, augmenting the patients’ 
strengths may provide an alternative strategy to increase a patient’s well-being. However, this aspect is 
particularly environment-dependent. For instance, while ASD patients have difficulties with complex 
information integration, they perform very well when focusing on a task. Likewise, while ADHD children 
have difficulties in sitting still in the class room, as adults they can do well as managers who have to 
multitask. Thus, rather than fitting them with the ‘standard’ environment shaped for the majority of the 
human population, the ISBS Panel recognizes that providing the special NDD patients with an 
environment that fosters their capacities may not only down-play their limitations, but also benefit the 
society, as well as reduce negative (e.g., stress-related) influences, thereby indirectly further alleviating 
some aspects of NDD pathobiology. Collectively, this emphasizes (for both animal and human research) 
the need to consider disorder-related symptoms in the ‘personalized’ context of the specific environment 
of individual patients. In addition, it is becoming critical to test the efficacy of environmental adjustments 
(as a supplement to other interventions) to enhance the capacities of those that are inflicted by aberrant 
neural development. 
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Figure 1. A general framework of major neurodevelopmental disorders (NDDs) and the larger 
‘NDD+’ spectrum of associated neuropsychiatric illnesses. ASD – autism spectrum disorder, ID – 
intellectual disability, CD – communication disorder, ADHD – attention deficit hyperactivity disorder, 
TSC – tuberous sclerosis complex, TD – tic disorders, MD – motor disorders, ME – microencephaly, LE 
– lissencephaly. Other NDDs include fetal alcohol syndrome (FAS) and related to it fetal alcohol 
spectrum disorders (FASD) under the ‘umbrella’ of alcohol-related neurodevelopmental disorder 
(ARND), as well as not shown here Down, Prader-Willi and Williams syndromes (Table 1). Additional 
disorders with neurodevelopmental trajectories include bipolar depression (BD) and schizophrenia (SZ), 
as well as some others, not shown here (e.g., early-onset types of trauma- and stress-related disorders 
(TSRD)), that forming the wider ‘NDD+’ spectrum.  
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Figure 2. The role of common environmental factors in pathogenesis of neurodevelopmental 
disorders (NDDs). Panel A illustrates selected post-conception prenatal and postnatal environmental 
factors. Prenatal environmental factors of maternal origin either directly cross the placenta, or alter 
placental function and thereby indirectly alter fetal neural development. The earlier the maternal 
environmental influences, the more global and diffuse the expected effects on fetal neural development. 
Although the newborn/child continues to be exposed to several maternal environmental factors 
postnatally, the microbiome, stress and the quality of parenting come into play, further shaping neural 
development. Importantly, all such environmental factors have the potency to increase risk for NDDs. 
Other potential environmental factors, not shown here but discussed in the text, include early sensory 
stimulation (e.g., environmental enrichment) and exercise (including both mental/cognitive and physical 
activity). Panel B summarizes the potential ‘vicious’ circle of NDD: aberrant neural development evokes 
behavioral (social, cognitive) deficits from early childhood, which results in deficient social and 
environmental interactions, necessary for shaping neural plasticity and adaptation in the maturing CNS. 
As a result, disease-provoked insufficient environmental stimulation may lead to additional impairments 
of neural development, in turn further worsening the existing NDD. Arrows denote potential treatments, 
including reducing NDD symptoms in affected individuals (T1) or improving social interactions of others 
with the patients (T2). Inset: An interesting example of potential complex dual relationship between 
aberrant neural development, NDDs and other neuropsychiatric disorders, such as post-traumatic stress 
disorder (PTSD). In one case, an early childhood trauma triggers both an early-onset subtype of PTSD 
and aberrant neural development (which makes subsequent PTSD worse). Alternatively, the pre-existing 
aberrant neural development may predispose an individual to an adult-onset subtype of PTSD (e.g., 
evoked by exposure to a severe trauma as adults). Albeit not the main focus of this review, such dual 
interplay between NDDs and other brain disorders beyond the NDD spectrum merits further scrutiny in 
both clinical and preclinical models.  
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Figure 3. Clustering of differentially expressed genes in the developing cortex of rodents. This 
diagram show typical patterns of gene expression clusters against time in postnatal weeks, grouped into 
"umbrella” categories (adapted from [173] and complemented with findings from [198]). This graph 
illustrates that gene expression patterns change markedly across development, rendering gene expression 
data at only one single time point uninformative. 
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Table 1. Selected genes involved in neurodevelopmental disorders (NDDs). These genes represent 
those discussed above, and do not serve as an exhaustive list of genetic mutations seen in all the NDDs 
[88].  
Disorder Genes involves (encoded proteins) Cellular function 
Microcephaly CASC5 (Casc5),CEP152 (Centrosomal protein of 152 
kDa), STIL (SCL-interrupting locus protein) and others 
[72, 76, 115, 164]  
Centrosome/centriole function; 
neuroprogenitor proliferation 
Lissencephaly DCX (Doublecortin) and LIS1 (Platelet-activating factor 
acetylhydrolase IB subunit alpha) [154] 
Cortical migration and patterning; 
neuroprogenitor proliferation 
Fragile X syndrome 
(FXS) 
FMR1 (Fragile X mental retardation protein) [143] Negative regulator of mRNA 
translation 
Angelman syndrome 
(AS) 
Prader-Willi 
syndrome 
UBE3A (Ubiquitin-protein ligase E3A) [110] 
  
SNORD116 among others [52] 
Targets proteins for degradation in 
the proteasome 
Modifies other small non-coding 
RNAs 
Tuberous sclerosis 
complex (TSC) 
Williams syndrome 
TSC1 (Hamartin) and TSC2 (Tuberin) [44] 
 
CLIP2, ELN, GTF2I, GTF2IRD1, and LIMK1, among 
others [157] 
Cellular proliferation via mTOR 
regulation; axon guidance 
Microtubule organization (CLIP2), 
Transcription (GTF2I, GTF2IRD1) 
and brain development (LIMK1) 
Autism spectrum 
disorders (ASD) 
NLGN3 (Neuroligin-3), NLGN4 (Neuroligin-4), NRXN1 
(Neurexin-1) and others [73, 97, 108]  
Synaptic scaffolding and signal 
transduction 
Non-syndromic 
intellectual disability 
(ID) 
SYNGAP1 (synaptic Ras-GTP activating protein 1), 
SNAP25 (synaptosomal-associated protein 25) and others 
[75, 81, 105]  
Synaptic function and 
neurotransmission 
Attention deficit 
hyperactivity disorder 
(ADHD) 
SNAP25 (synaptosomal-associated protein 25), DRD4 
(dopamine receptor D4), DRD5 (dopamine receptor D5), 
SLC6A3 (dopamine transporter), SLC6A4 (serotonin 
transporter SERT), HTR1B (serotonin receptor 1B) [74, 
119]  
Neurotransmission 
Rett syndrome (RTT) 
 
Down syndrome 
Schizophrenia 
MECP2 (Methyl-CpG binding protein 2) [33] 
 
Trisomy 21 (~97% of cases) [12] 
Many genes, including the complement component 4 
(C4) in the MHC locus [2, 14] 
Binding of methylated DNA, 
modulation of transcription 
Various 
Neural function and immune 
regulation 
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Table 2. Selected drugs used to treat common neurodevelopmental disorders (see [88] for details).  
Drugs Main profile and mechanism of action Disorders 
treated 
Risperidone (Risperdal) Atypical antipsychotic, blocks D2 and 5-HT2A receptors  Tics, ASD 
Haloperidol (Haldol) Typical antipsychotic (neuroleptic), blocks D2 receptors Tics 
Clonidine (Catapres) Sympatolytic α2 adrenergic- and imidazoline receptor agonist Tics, ADHD 
Atomoxetine (Strattera)  Non-stimulant norepinephrine reuptake inhibitor ADHD 
Methylphenidat (Ritalin) Stimulant, dopamine-norepinephrine reuptake inhibitor ADHD 
Ziprasidone (Geodon) Blocker ofdopamine/serotonin receptors and monoamine reuptake ASD 
Buspirone (Buspar) Anxiolytic, serotonin 5-HT1A receptor partial agonist ADHD, ASD 
Amphetamine (Adderal) Stimulant, monoamine reuptake inhibitor ADHD 
Dextroamphetamine 
(Dexedrine) 
Stimulant, monoamine reuptake inhibitor ADHD 
SSRIs Antidepressants, selective serotonin reuptake inhibitors ASD, ADHD 
 
 
